Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (175) 175
life sciences & biomedicine (172) 172
humans (154) 154
male (91) 91
female (84) 84
aged (71) 71
middle aged (64) 64
otorhinolaryngology (61) 61
audiology & speech-language pathology (47) 47
cardiovascular system & cardiology (46) 46
adult (45) 45
biological and medical sciences (33) 33
medical sciences (32) 32
aged, 80 and over (31) 31
anticoagulants (30) 30
stroke (30) 30
abridged index medicus (27) 27
atrial fibrillation (27) 27
treatment outcome (27) 27
cardiac & cardiovascular systems (26) 26
risk factors (26) 26
peripheral vascular disease (24) 24
stroke - prevention & control (23) 23
aspirin (21) 21
hemorrhage - chemically induced (21) 21
atrial fibrillation - drug therapy (19) 19
hearing impairment (19) 19
surgery (19) 19
young adult (19) 19
analysis (18) 18
bleeding (18) 18
clinical trials (18) 18
hearing loss (18) 18
hearing aids (17) 17
hematology (17) 17
hemorrhage (17) 17
neurosciences & neurology (17) 17
research (17) 17
general & internal medicine (16) 16
medicine, general & internal (16) 16
ophthalmology (16) 16
prospective studies (16) 16
warfarin (16) 16
anticoagulants - adverse effects (15) 15
atrial fibrillation - complications (15) 15
audiometry (15) 15
child (15) 15
drug therapy (15) 15
audiology (14) 14
clinical neurology (14) 14
health aspects (14) 14
prevention (14) 14
reproducibility of results (14) 14
time factors (14) 14
administration, oral (13) 13
adolescent (13) 13
anticoagulants - therapeutic use (13) 13
care and treatment (13) 13
patients (13) 13
surveys and questionnaires (13) 13
audiometry, pure-tone (12) 12
cardiovascular diseases (12) 12
hearing loss - diagnosis (12) 12
medicin och hälsovetenskap (12) 12
vitamin k (12) 12
anticoagulants - administration & dosage (11) 11
aspirin - adverse effects (11) 11
child, preschool (11) 11
children (11) 11
cohort studies (11) 11
hearing (11) 11
randomized controlled trials as topic (11) 11
rivaroxaban (11) 11
telemedicine (11) 11
animals (10) 10
aspirin - therapeutic use (10) 10
automated audiometry (10) 10
cardiovascular disease (10) 10
dabigatran (10) 10
diagnosis (10) 10
dosage and administration (10) 10
double-blind method (10) 10
fibrinolytic agents - therapeutic use (10) 10
medical research (10) 10
mortality (10) 10
neurology (10) 10
usage (10) 10
cardiovascular (9) 9
fibrinolytic agents - adverse effects (9) 9
health care sciences & services (9) 9
myocardial infarction (9) 9
stroke - etiology (9) 9
thrombosis (9) 9
adults (8) 8
age (8) 8
age factors (8) 8
anticoagulation (8) 8
auditory threshold (8) 8
blood coagulation - drug effects (8) 8
bone conduction (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
by Diener, Hans-Christoph, Prof, Dr and Eikelboom, John, Prof and Connolly, Stuart J, Prof and Joyner, Campbell D, Prof and Hart, Robert G, Prof and Lip, Gregory YH, Prof and O'Donnell, Martin, MD and Hohnloser, Stefan H, Prof and Hankey, Graeme J, Prof and Shestakovska, Olga, MSc and Yusuf, Salim, Prof and for the AVERROES steering committee and investigators and AVERROES Steering Comm Investigato and AVERROES Steering Committee and Investigators
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 3, pp. 225 - 231
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Pyrazoles - therapeutic use | Ischemic Attack, Transient - drug therapy | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Stroke - drug therapy | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Female | Aged | Aspirin - therapeutic use | Pyridones - therapeutic use | Stroke (Disease) | Care and treatment | Aspirin | Ischemia | Atrial fibrillation | Abnormalities | Clinical trials | Muscle contraction | Index Medicus | Stroke | Fibrillation | Transient ischemic attack | Regression analysis | Age | Bleeding | Embolism | Risk factors | Vitamin K
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Apixaban in Patients with Atrial Fibrillation
by Connolly, Stuart J and Eikelboom, John and Joyner, Campbell and Diener, Hans-Christoph and Hart, Robert and Golitsyn, Sergey and Flaker, Greg and Avezum, Alvaro and Hohnloser, Stefan H and Diaz, Rafael and Talajic, Mario and Zhu, Jun and Pais, Prem and Budaj, Andrzej and Parkhomenko, Alexander and Jansky, Petr and Commerford, Patrick and Tan, Ru San and Sim, Kui-Hian and Lewis, Basil S and Lewis, Gayle and Van Mieghem, Walter and Lip, Gregory Y.H and Kim, Jae Hyung and Lanas-Zanetti, Fernando and Gonzalez-Hermosillo, Antonio and Dans, Antonio L and Munawar, Muhammad and O'Donnell, Martin and Lawrence, John and Afzal, Rizwan and Yusuf, Salim and AVERROES Steering Committee and Investigators
The New England journal of medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 9, pp. 806 - 817
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pyrazoles - therapeutic use | Factor Xa Inhibitors | Humans | Middle Aged | Male | Fibrinolytic Agents - adverse effects | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Female | Stroke - epidemiology | Aspirin - therapeutic use | Embolism - epidemiology | Pyrazoles - adverse effects | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Proportional Hazards Models | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Cardiac arrhythmia | Medical research | Stroke | Aspirin | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
by Eikelboom, John W and Connolly, Stuart J and Bosch, Jackie and Dagenais, Gilles R and Hart, Robert G and Shestakovska, Olga and Diaz, Rafael and Alings, Marco and Lonn, Eva M and Anand, Sonia S and Widimsky, Petr and Hori, Masatsugu and Avezum, Alvaro and Piegas, Leopoldo S and Branch, Kelley R.H and Probstfield, Jeffrey and Bhatt, Deepak L and Zhu, Jun and Liang, Yan and Maggioni, Aldo P and Lopez-Jaramillo, Patricio and O’Donnell, Martin and Kakkar, Ajay K and Fox, Keith A.A and Parkhomenko, Alexander N and Ertl, Georg and Störk, Stefan and Keltai, Matyas and Ryden, Lars and Pogosova, Nana and Dans, Antonio L and Lanas, Fernando and Commerford, Patrick J and Torp-Pedersen, Christian and Guzik, Tomek J and Verhamme, Peter B and Vinereanu, Dragos and Kim, Jae-Hyung and Tonkin, Andrew M and Lewis, Basil S and Felix, Camilo and Yusoff, Khalid and Steg, P. Gabriel and Metsarinne, Kaj P and Cook Bruns, Nancy and Misselwitz, Frank and Chen, Edmond and Leong, Darryl and Yusuf, Salim and COMPASS Investigators
The New England journal of medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
by Khorana, Alok A and Soff, Gerald A and Kakkar, Ajay K and Vadhan-Raj, Saroj and Riess, Hanno and Wun, Ted and Streiff, Michael B and Garcia, David A and Liebman, Howard A and Belani, Chandra P and O’Reilly, Eileen M and Patel, Jai N and Yimer, Habte A and Wildgoose, Peter and Burton, Paul and Vijapurkar, Ujjwala and Kaul, Simrati and Eikelboom, John and McBane, Robert and Bauer, Kenneth A and Kuderer, Nicole M and Lyman, Gary H and CASSINI Investigators
The New England journal of medicine, ISSN 0028-4793, 02/2019, Volume 380, Issue 8, pp. 720 - 728
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Incidence | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Neoplasms - complications | Venous Thromboembolism - prevention & control | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Factor Xa Inhibitors - adverse effects | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Hemorrhage - chemically induced | Rivaroxaban - therapeutic use | Prevention | Rivaroxaban | Cancer patients | Usage | Safety and security measures | Thromboembolism | Health aspects | Risk factors | Intervention | Statistical analysis | Oncology | Thrombosis | Patients | Lymphoma | Bleeding | Embolism | Disease prevention | Ultrasonic imaging | Health risk assessment | Cancer | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dabigatran versus Warfarin in Patients with Atrial Fibrillation
by Connolly, Stuart J and Ezekowitz, Michael D and Yusuf, Salim and Eikelboom, John and Oldgren, Jonas and Parekh, Amit and Pogue, Janice and Reilly, Paul A and Themeles, Ellison and Varrone, Jeanne and Wang, Susan and Alings, Marco and Xavier, Denis and Zhu, Jun and Diaz, Rafael and Lewis, Basil S and Darius, Harald and Diener, Hans-Christoph and Joyner, Campbell D and Wallentin, Lars and the RE-LY Steering Committee and Investigators and RE-LY Steering Comm & Investigator and RE-LY Steering Committee and Investigators
The New England journal of medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 12, pp. 1139 - 1151
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | General aspects | Medical sciences | Cardiac dysrhythmias | Myocardial Infarction - epidemiology | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Warfarin - adverse effects | Male | Dyspepsia - chemically induced | Dabigatran | Warfarin - administration & dosage | Warfarin - therapeutic use | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Liver - drug effects | Atrial Fibrillation - mortality | Female | Stroke - epidemiology | Benzimidazoles - adverse effects | Embolism - epidemiology | Stroke - prevention & control | Pyridines - administration & dosage | Double-Blind Method | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Proportional Hazards Models | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Chi-Square Distribution | Aged | Prodrugs - therapeutic use | Hemorrhage - chemically induced | Medical research | Cardiac arrhythmia | Anticoagulants | Cardiovascular disease | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Idarucizumab for Dabigatran Reversal
by Pollack, Charles V and Reilly, Paul A and Eikelboom, John and Glund, Stephan and Verhamme, Peter and Bernstein, Richard A and Dubiel, Robert and Huisman, Menno V and Hylek, Elaine M and Kamphuisen, Pieter W and Kreuzer, Jörg and Levy, Jerrold H and Sellke, Frank W and Stangier, Joachim and Steiner, Thorsten and Wang, Bushi and Kam, Chak-Wah and Weitz, Jeffrey I
The New England journal of medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 6, pp. 511 - 520
ANTIDOTE | STROKE | WARFARIN | SAFETY | ATRIAL-FIBRILLATION | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thrombosis - chemically induced | Prospective Studies | beta-Alanine - blood | Humans | Middle Aged | beta-Alanine - antagonists & inhibitors | Male | Dabigatran | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - blood | Aged, 80 and over | Female | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Benzimidazoles - blood | Antibodies, Monoclonal, Humanized - adverse effects | beta-Alanine - adverse effects | Thrombosis - epidemiology | Anticoagulants - adverse effects | Benzimidazoles - antagonists & inhibitors | Anticoagulants - blood | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Aged | Hemorrhage - chemically induced | Infusions, Intravenous | Usage | Care and treatment | Clinical trials | Blood clotting | Dabigatran etexilate | Dosage and administration | Vitamin K | Anticoagulants | Intravenous administration | Hemostasis | Surgery | Thrombin | Health risk assessment | Clotting | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
by Pollack, Charles V and Reilly, Paul A and van Ryn, Joanne and Eikelboom, John W and Glund, Stephan and Bernstein, Richard A and Dubiel, Robert and Huisman, Menno V and Hylek, Elaine M and Kam, Chak-Wah and Kamphuisen, Pieter W and Kreuzer, Jörg and Levy, Jerrold H and Royle, Gordon and Sellke, Frank W and Stangier, Joachim and Steiner, Thorsten and Verhamme, Peter and Wang, Bushi and Young, Laura and Weitz, Jeffrey I
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 431 - 441
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Dabigatran - adverse effects | Thrombosis - chemically induced | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Humans | Middle Aged | Dabigatran - blood | Drug Hypersensitivity | Male | Dabigatran - antagonists & inhibitors | Anticoagulants - adverse effects | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Time Factors | Aged, 80 and over | Adult | Antibodies - blood | Female | Aged | Hemorrhage - chemically induced | Infusions, Intravenous | Antibodies, Monoclonal, Humanized - immunology | Thrombin Time | Anticoagulants | Intravenous administration | Mortality | Thrombin | Preventive medicine | Patients | Thrombosis | Hemorrhage | Bleeding | Clotting | Studies | Hemostasis | Surgery | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Hearing Loss and Depression in Older Adults: A Systematic Review and Meta-analysis
by Lawrence, Blake J and Jayakody, Dona M P and Bennett, Rebecca J and Eikelboom, Robert H and Gasson, Natalie and Friedland, Peter L
The Gerontologist, ISSN 0016-9013, 04/2020, Volume 60, Issue 3, pp. e137 - e154
Hearing impairment | Mental health | Audiology | Gerontology | Life Sciences & Biomedicine | Geriatrics & Gerontology | Science & Technology | Older people | Bias | Systematic review | Research design | Mental depression | Meta-analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights